TY  - JOUR
AU  - Manzanares-Martin, Barbara
AU  - Cebrián Aranda, Arancha
AU  - Del Puerto-Nevado, Laura
AU  - González, Rafael
AU  - Solanes, Sonia
AU  - Gómez-España, Maria Auxiliadora
AU  - García-Foncillas, Jesús
AU  - Aranda, Enrique
PY  - 2021
DO  - 10.1136/jitc-2020-001705
UR  - http://hdl.handle.net/10668/17550
T2  - Journal for immunotherapy of cancer
AB  - Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell...
LA  - en
KW  - antibodies
KW  - biomarkers
KW  - natural killer t-cells
KW  - neoplasm
KW  - translational medical research
KW  - tumor
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents, Immunological
KW  - Biomarkers, Tumor
KW  - Cetuximab
KW  - Child
KW  - Child, Preschool
KW  - Clinical Decision-Making
KW  - Colorectal Neoplasms
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - Haplotypes
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - Patient Selection
KW  - Phenotype
KW  - Predictive Value of Tests
KW  - Progression-Free Survival
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Receptors, KIR
KW  - Risk Assessment
KW  - Risk Factors
KW  - Spain
KW  - Young Adult
TI  - Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.
TY  - research article
VL  - 9
ER  -